Avastin bevacizumab: Phase II data

The open-label, international Phase II RTOG 0615 trial in 44 evaluable patients with stage IIB-IVB nasopharyngeal cancer showed that Avastin plus cisplatin, radiation therapy and fluorouracil led to estimated 2-year PFS and OS rates of 74.7% and 90.9%, respectively, at a median follow-up of 2.5 years. Additionally, estimated 2-year locoregional progression-free and distant metastasis-free intervals were 83.7% and 90.8%, respectively. There were no grade 3/4 hemorrhages or grade 5 adverse events. Nine patients had a treatment-related grade 1/2 hemorrhage and 9 patients had >=1 grade 4 blood or bone marrow-related complication. Data were published in The Lancet Oncology. ...